DDInter231 DDInter1180
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Brexpiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Brexpiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Brexpiprazole {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Brexpiprazole {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Brexpiprazole may lead to a major life threatening interaction when taken with Bupropion
Brexpiprazole may lead to a major life threatening interaction when taken with Fedratinib